Patents by Inventor Francoise Pflumio

Francoise Pflumio has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 10407695
    Abstract: The present invention provides nucleic acid, vectors, viruses, and recombinant cells comprising triple-stranded structures, such as those resulting from central initiation and termination of HIV-1 reverse transcription at the center of HIV-1 linear DNA genomes. These triplex structures can act as a cis-determinant of HIV-1 DNA nuclear import, allowing infection of non-dividing target cells. In one aspect, the presence of the DNA triplex sequence in an HIV vector strongly stimulates gene transfer in hematopoietic stem cells. The invention also provides methods of using these triplex structures for making recombinant cells, as well as methods of using the recombinant cells to express proteins of interest both in vitro and in vivo.
    Type: Grant
    Filed: February 4, 2015
    Date of Patent: September 10, 2019
    Assignees: Institut Pasteur, Institut National de la Santé et de la Recherche Médicale, Centre National de la Recherche Scientifique
    Inventors: Pierre Charneau, Veronique Zennou, Francoise Pflumio, Aude Sirven, Anne Dubart Kupperschmitt
  • Publication number: 20190119699
    Abstract: The present invention provides nucleic acid, vectors, viruses, and recombinant cells comprising triple-stranded structures, such as those resulting from central initiation and termination of HIV-1 reverse transcription at the center of HIV-1 linear DNA genomes. These triplex structures can act as a cis-determinant of HIV-1 DNA nuclear import, allowing infection of non-dividing target cells. In one aspect, the presence of the DNA triplex sequence in an HIV vector strongly stimulates gene transfer in hematopoietic stem cells. The invention also provides methods of using these triplex structures for making recombinant cells, as well as methods of using the recombinant cells to express proteins of interest both in vitro and in vivo.
    Type: Application
    Filed: July 24, 2018
    Publication date: April 25, 2019
    Applicants: INSTITUT PASTEUR, CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE, INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE
    Inventors: Pierre CHARNEAU, Veronique ZENNOU, Francoise PFLUMIO, Aude SIRVEN, Anne DUBART KUPPERSCHMITT
  • Publication number: 20180346928
    Abstract: The present invention provides nucleic acid, vectors, viruses, and recombinant cells comprising triple-stranded structures, such as those resulting from central initiation and termination of HIV-1 reverse transcription at the center of HIV-1 linear DNA genomes. These triplex structures can act as a cis-determinant of HIV-1 DNA nuclear import, allowing infection of non-dividing target cells. In one aspect, the presence of the DNA triplex sequence in an HIV vector strongly stimulates gene transfer in hematopoietic stem cells. The invention also provides methods of using these triplex structures for making recombinant cells, as well as methods of using the recombinant cells to express proteins of interest both in vitro and in vivo.
    Type: Application
    Filed: July 24, 2018
    Publication date: December 6, 2018
    Applicants: INSTITUT PASTEUR, CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE, INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE
    Inventors: Pierre CHARNEAU, Veronique ZENNOU, Francoise PFLUMIO, Aude SIRVEN, Anne DUBART KUPPERSCHMITT
  • Patent number: 9238824
    Abstract: The present invention provides nucleic acid, vectors, viruses, and recombinant cells comprising triple-stranded structures, such as those resulting from central initiation and termination of HIV-1 reverse transcription at the center of HIV-1 linear DNA genomes. These triplex structures can act as a cis-determinant of HIV-1 DNA nuclear import, allowing infection of non-dividing target cells. In one aspect, the presence of the DNA triplex sequence in an HIV vector strongly stimulates gene transfer in hematopoietic stem cells. The invention also provides methods of using these triplex structures for making recombinant cells, as well as methods of using the recombinant cells to express proteins of interest both in vitro and in vivo.
    Type: Grant
    Filed: July 15, 2013
    Date of Patent: January 19, 2016
    Assignees: Institut Pasteur, Institut National de la Santé et de la Recherche Médicale, Centre National de la Recherche Scientifique
    Inventors: Pierre Charneau, Veronique Zennou, Francoise Pflumio, Aude Sirven, Anne Dubart Kupperschmitt
  • Publication number: 20150191745
    Abstract: The present invention provides nucleic acid, vectors, viruses, and recombinant cells comprising triple-stranded structures, such as those resulting from central initiation and termination of HIV-1 reverse transcription at the center of HIV-1 linear DNA genomes. These triplex structures can act as a cis-determinant of HIV-1 DNA nuclear import, allowing infection of non-dividing target cells. In one aspect, the presence of the DNA triplex sequence in an HIV vector strongly stimulates gene transfer in hematopoietic stem cells. The invention also provides methods of using these triplex structures for making recombinant cells, as well as methods of using the recombinant cells to express proteins of interest both in vitro and in vivo.
    Type: Application
    Filed: February 4, 2015
    Publication date: July 9, 2015
    Applicants: INSTITUT PASTEUR, CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE, INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE
    Inventors: Pierre CHARNEAU, Veronique ZENNOU, Francoise PFLUMIO, Aude SIRVEN, Anne DUBART KUPPERSCHMITT
  • Publication number: 20150011006
    Abstract: The present invention provides nucleic acid, vectors, viruses, and recombinant cells comprising triple-stranded structures, such as those resulting from central initiation and termination of HIV-1 reverse transcription at the center of HIV-1 linear DNA genomes. These triplex structures can act as a cis-determinant of HIV-1 DNA nuclear import, allowing infection of non-dividing target cells. In one aspect, the presence of the DNA triplex sequence in an HIV vector strongly stimulates gene transfer in hematopoietic stem cells. The invention also provides methods of using these triplex structures for making recombinant cells, as well as methods of using the recombinant cells to express proteins of interest both in vitro and in vivo.
    Type: Application
    Filed: July 15, 2013
    Publication date: January 8, 2015
    Applicants: Institut Pasteur, Institut National De La Sante Et De La Recherche Medicale, Centre National De La Recherche Scientifique
    Inventors: Pierre CHARNEAU, Veronique ZENNOU, Francoise PFLUMIO, Aude SIRVEN, Anne DUBART KUPPERSCHMITT
  • Patent number: 8512994
    Abstract: The present invention provides nucleic acid, vectors, viruses, and recombinant cells comprising triple-stranded structures, such as those resulting from central initiation and termination of HIV-1 reverse transcription at the center of HIV-1 linear DNA genomes. These triplex structures can act as a cis-determinant of HIV-1 DNA nuclear import, allowing infection of non-dividing target cells. In one aspect, the presence of the DNA triplex sequence in an HIV vector strongly stimulates gene transfer in hematopoietic stem cells. The invention also provides methods of using these triplex structures for making recombinant cells, as well as methods of using the recombinant cells to express proteins of interest both in vitro and in vivo.
    Type: Grant
    Filed: November 21, 2011
    Date of Patent: August 20, 2013
    Assignees: Institut Pasteur, Institut National de la Santé et de la Recherche Médicale, Centre National de la Recherche Scientifique
    Inventors: Pierre Charneau, Veronique Zennou, Francoise Pflumio, Aride Sirven, Anne Dubart
  • Patent number: 8512993
    Abstract: The present invention provides nucleic acid, vectors, viruses, and recombinant cells comprising triple-stranded structures, such as those resulting from central initiation and termination of HIV-1 reverse transcription at the center of HIV-1 linear DNA genomes. These triplex structures can act as a cis-determinant of HIV-1 DNA nuclear import, allowing infection of non-dividing target cells. In one aspect, the presence of the DNA triplex sequence in an HIV vector strongly stimulates gene transfer in hematopoietic stem cells. The invention also provides methods of using these triplex structures for making recombinant cells, as well as methods of using the recombinant cells to express proteins of interest both in vitro and in vivo.
    Type: Grant
    Filed: November 21, 2011
    Date of Patent: August 20, 2013
    Assignees: Institut Pasteur, Institut National de la Santé et de la Recherche Médicale, Centre National de la Recherche Scientifique
    Inventors: Pierre Charneau, Veronique Zennou, Francoise Pflumio, Aride Sirven, Anne Dubart
  • Publication number: 20120122963
    Abstract: The present invention provides nucleic acid, vectors, viruses, and recombinant cells comprising triple-stranded structures, such as those resulting from central initiation and termination of HIV-1 reverse transcription at the center of HIV-1 linear DNA genomes. These triplex structures can act as a cis-determinant of HIV-1 DNA nuclear import, allowing infection of non-dividing target cells. In one aspect, the presence of the DNA triplex sequence in an HIV vector strongly stimulates gene transfer in hematopoietic stem cells. The invention also provides methods of using these triplex structures for making recombinant cells, as well as methods of using the recombinant cells to express proteins of interest both in vitro and in vivo.
    Type: Application
    Filed: November 21, 2011
    Publication date: May 17, 2012
    Inventors: Pierre CHARNEAU, Veronique Zennou, Francoise Pflumio, Aride Sirven, Anne Dubart
  • Publication number: 20120122204
    Abstract: The present invention provides nucleic acid, vectors, viruses, and recombinant cells comprising triple-stranded structures, such as those resulting from central initiation and termination of HIV-1 reverse transcription at the center of HIV-1 linear DNA genomes. These triplex structures can act as a cis-determinant of HIV-1 DNA nuclear import, allowing infection of non-dividing target cells. In one aspect, the presence of the DNA triplex sequence in an HIV vector strongly stimulates gene transfer in hematopoietic stem cells. The invention also provides methods of using these triplex structures for making recombinant cells, as well as methods of using the recombinant cells to express proteins of interest both in vitro and in vivo.
    Type: Application
    Filed: November 21, 2011
    Publication date: May 17, 2012
    Inventors: Pierre Charneau, Veronique Zennou, Francoise Pflumio, Aride Sirven, Anne Dubart
  • Patent number: 8093042
    Abstract: The present invention provides nucleic acid, vectors, viruses, and recombinant cells comprising triple-stranded structures, such as those resulting from central initiation and termination of HIV-1 reverse transcription at the center of HIV-1 linear DNA genomes. These triplex structures can act as a cis-determinant of HIV-1 DNA nuclear import, allowing infection of non-dividing target cells. In one aspect, the presence of the DNA triplex sequence in an HIV vector strongly stimulates gene transfer in hematopoietic stem cells. The invention also provides methods of using these triplex structures for making recombinant cells, as well as methods of using the recombinant cells to express proteins of interest both in vitro and in vivo.
    Type: Grant
    Filed: December 1, 2005
    Date of Patent: January 10, 2012
    Assignees: Institut Pasteur, Institut National de la Santé et de la Recherche Médicale
    Inventors: Pierre Charneau, Veronique Zennou, Francoise Pflumio, Aride Sirven, Anne Dubart
  • Publication number: 20070224679
    Abstract: The present invention provides nucleic acid, vectors, viruses, and recombinant cells comprising triple-stranded structures, such as those resulting from central initiation and termination of HIV-1 reverse transcription at the center of HIV-1 linear DNA genomes. These triplex structures can act as a cis-determinant of HIV-1 DNA nuclear import, allowing infection of non-dividing target cells. In one aspect, the presence of the DNA triplex sequence in an HIV vector strongly stimulates gene transfer in hematopoietic stem cells. The invention also provides methods of using these triplex structures for making recombinant cells, as well as methods of using the recombinant cells to express proteins of interest both in vitro and in vivo.
    Type: Application
    Filed: December 1, 2005
    Publication date: September 27, 2007
    Inventors: Pierre Charneau, Veronique Zennou, Francoise Pflumio, Aride Sirven, Anne Dubart
  • Publication number: 20050163760
    Abstract: The present invention provides novel methods for delivering cells, particularly modified cells to the central nervous system (CNS). The purpose of this invention is to present a method that provides sustained delivery of a molecule to the central nervous system, thereby increasing the bioavailability of the molecule and lengthening the possible duration of treatment.
    Type: Application
    Filed: December 6, 2002
    Publication date: July 28, 2005
    Inventors: Nathalie Cartier-Lacave, Patrick Aubourg, Muriel Ashueur, Sonia Benhamida, Francoise Pflumio
  • Publication number: 20030194392
    Abstract: The present ivention provides nucleic acid, vectors, viruses, and recombinant cells comprising triple-stranded structures, such as those resulting from central initiation and termination of HIV-1 reverse transcription at the center of HIV-1 linear DNA genomes. These triplex structures can act as a cis-determinant of HIV-1 DNA nuclear import, allowing infection of non-dividing target cells. In one aspect, the presence of the DNA triplex sequence in an HIV vector strongly stimulates gene transfer in hematopoietic stem cells. The invention also provides methods of using these triplex structures for making recombinant cells, as well as methods of using the recombinant cells to express proteins of interest both in vitro and in vivo.
    Type: Application
    Filed: April 10, 2002
    Publication date: October 16, 2003
    Inventors: Pierre Charneau, Veronique Zennou, Francoise Pflumio, Aude Sirven, Anne Dubart Kupperschmitt